Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

The findings of two studies, published in The Lancet Infectious Diseases journal, reveal that by 2016–2018 malaria parasites resistant to both artemisinin and its widely used partner drug piperaquine represented more than 80% of the parasites circulating in northeast Thailand and Vietnam, despite having only emerged in western Cambodia in 2008.

Similar stories

Nigeria rolls out new Oxford R21 malaria vaccine

On Thursday, Nigeria announced the regulatory approval and launch of the new R21/Matrix-M™ malaria vaccine that will be freely administered to recipients. This marks a significant milestone in the country’s fight against the deadly disease.